These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21593572)

  • 1. Amyloid-β₄₂ is associated with cognitive impairment in healthy elderly and subjective cognitive impairment.
    Rolstad S; Berg AI; Bjerke M; Blennow K; Johansson B; Zetterberg H; Wallin A
    J Alzheimers Dis; 2011; 26(1):135-42. PubMed ID: 21593572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid biomarkers mirror rate of cognitive decline.
    Rolstad S; Berg AI; Bjerke M; Johansson B; Zetterberg H; Wallin A
    J Alzheimers Dis; 2013; 34(4):949-56. PubMed ID: 23313924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
    J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tau and Amyloid-β Cerebrospinal Fluid Biomarkers have Differential Relationships with Cognition in Mild Cognitive Impairment.
    Malpas CB; Saling MM; Velakoulis D; Desmond P; O'Brien TJ;
    J Alzheimers Dis; 2015; 47(4):965-75. PubMed ID: 26401775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-Tau is Associated with Objective Memory Decline Over Two Years in Persons Seeking Help for Subjective Cognitive Decline: A Report from the Gothenburg-Oslo MCI Study.
    Hessen E; Nordlund A; Stålhammar J; Eckerström M; Bjerke M; Eckerström C; Göthlin M; Fladby T; Reinvang I; Wallin A
    J Alzheimers Dis; 2015; 47(3):619-28. PubMed ID: 26401697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment.
    Gonzales MM; Insel PS; Nelson C; Tosun D; Schöll M; Mattsson N; Sacuiu S; Bickford D; Weiner MW; Mackin RS;
    Int J Geriatr Psychiatry; 2018 Oct; 33(10):1305-1311. PubMed ID: 29953668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions between amyloid-β and tau in cerebrospinal fluid of people with mild cognitive impairment and Alzheimer's disease.
    Kristofikova Z; Ricny J; Kolarova M; Vyhnalek M; Hort J; Laczo J; Sirova J; Ripova D
    J Alzheimers Dis; 2014; 42 Suppl 3():S91-8. PubMed ID: 24670397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI).
    Nathan PJ; Lim YY; Abbott R; Galluzzi S; Marizzoni M; Babiloni C; Albani D; Bartres-Faz D; Didic M; Farotti L; Parnetti L; Salvadori N; Müller BW; Forloni G; Girtler N; Hensch T; Jovicich J; Leeuwis A; Marra C; Molinuevo JL; Nobili F; Pariente J; Payoux P; Ranjeva JP; Rolandi E; Rossini PM; Schönknecht P; Soricelli A; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB;
    Neurobiol Aging; 2017 May; 53():1-10. PubMed ID: 28189924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.
    Rami L; Fortea J; Bosch B; Solé-Padullés C; Lladó A; Iranzo A; Sánchez-Valle R; Molinuevo JL
    J Alzheimers Dis; 2011; 23(2):319-26. PubMed ID: 21098971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
    Parnetti L; Chiasserini D; Eusebi P; Giannandrea D; Bellomo G; De Carlo C; Padiglioni C; Mastrocola S; Lisetti V; Calabresi P
    J Alzheimers Dis; 2012; 29(1):229-38. PubMed ID: 22232006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Patients with mild cognitive impairment and a reduced CSF Aβ₁₋₄₂ protein progress rapidly to Alzheimer's disease].
    Monge-Argilés JA; Sánchez-Payá J; Muñoz-Ruiz C; Pampliega-Pérez A; Gómez-López MJ; Rodríguez Borja E; Montoya-Gutiérrez J; Leiva-Santana C
    Neurologia; 2012 Jan; 27(1):28-33. PubMed ID: 21621878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment.
    Selnes P; Aarsland D; Bjørnerud A; Gjerstad L; Wallin A; Hessen E; Reinvang I; Grambaite R; Auning E; Kjærvik VK; Due-Tønnessen P; Stenset V; Fladby T
    J Alzheimers Dis; 2013; 33(3):723-36. PubMed ID: 23186987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistically Derived Subtypes and Associations with Cerebrospinal Fluid and Genetic Biomarkers in Mild Cognitive Impairment: A Latent Profile Analysis.
    Eppig JS; Edmonds EC; Campbell L; Sanderson-Cimino M; Delano-Wood L; Bondi MW;
    J Int Neuropsychol Soc; 2017 Aug; 23(7):564-576. PubMed ID: 28578726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
    Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
    J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's disease.
    Le Bastard N; Aerts L; Sleegers K; Martin JJ; Van Broeckhoven C; De Deyn PP; Engelborghs S
    J Alzheimers Dis; 2013; 33(3):807-22. PubMed ID: 23034521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline Neurodegeneration Influences the Longitudinal Effects of Tau on Cognition.
    Ng KP; Cheng GH; Yatawara C; Rosa-Neto P; Gauthier S; Kandiah N;
    J Alzheimers Dis; 2021; 82(1):159-167. PubMed ID: 33998536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.